Navigation Links
Pharmacopeia to Present at The Roth 20th Annual OC Growth Stock Conference
Date:2/13/2008

PRINCETON, N.J., Feb. 13 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that Dr. Leslie J. Browne, President and Chief Executive Officer, will deliver a corporate presentation at the Roth 20th Annual OC Growth Stock Conference. The conference will be held February 18-21, 2008, at The Ritz Carlton Laguna Niguel in Dana Point, CA.

Dr. Browne's presentation will take place at 10:30 a.m. local time on Thursday, February 21st. The presentation will include an overview of the company's drug development pipeline, including an update on its internal clinical programs, PS433540 (DARA), which is progressing in Phase 2, and PS178990 (SARM), which is currently in Phase 1. A live webcast and 90-day archive of the presentation can be accessed at http://www.pharmacopeia.com.

ABOUT PHARMACOPEIA

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Contact:

Amy P. Sharpless

Corporate Communications

(609) 452-3643

ir_pr@pcop.com

This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS031291, a product candidate from its chemokine receptor CCR1 program, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, PS178990 and PS031291, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Schering-Plough and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. USP publishes Spanish edition of United States Pharmacopeia and National Formulary
2. USP Publishes Spanish Edition of United States Pharmacopeia and National Formulary
3. U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide
4. US Pharmacopeia partners with Quantros to enhance the MEDMARX patient safety reporting program
5. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
6. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
7. Pharmacopeia Announces Senior Additions to Management Team
8. Pet DRx to Present at Roth 20th Annual OC Growth Stock Conference
9. AtriCure to Present at Roth Capital Partners 20th Annual OC Conference
10. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
11. Inexpensive Online Pain Education Program for Physicians as Effective as Live Presentations by National Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Chesapeake, VA (PRWEB) , ... March 22, 2017 ... ... offering asset protection assistance and financial consultations to families and business owners in ... raise support for the local American Cancer Society Relay For Life event. , ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... related services to communities across eastern Texas, is announcing a charity drive in ... to hungry children and adults. , Consistently a top-rated nonprofit organization for ...
(Date:3/22/2017)... ... , ... Schneider Insurance and Financial, a southern Montana firm providing asset protection ... is launching a charity event aimed at raising local support for Zoo Montana. , ... and is home to a broad variety of animals from all over the world. ...
(Date:3/22/2017)... ... March 22, 2017 , ... Chris Humphrey Insurance Agency, a North Carolina ... throughout the coastal plains region, is initiating a charity event to raise support for ... first diagnosed with leukemia on a Friday evening in September 2014. At the time, ...
(Date:3/22/2017)... ... March 22, 2017 , ... College basketball surges to its peak during ... recruiting – that is, recruiting people to be foster parents. Through a televised spot, ... are in foster care due to abuse, neglect and other family challenges. People who ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 23, 2017 ... 2021, a latest research report. The global vagus nerve ... shift of surgeons focus toward minimally invasive VNS procedures. ... limited to few developed countries having high standards of ... ...
(Date:3/22/2017)... , 22 de marzo de 2017   ... líder de soluciones de productos y servicios para ... que ha adquirido EPL Archives, Inc., una organización ... clientes en todo el ciclo de vida de ... una muestra de archivo, almacenamiento de documentos y ...
(Date:3/22/2017)... , Mar. 22, 2017 Research and ... Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 10.9% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Medicine Technology: